The Fugl-Meyer Upper Extremity: One Score, Several MCIDs

Reviewed by a board-certified NCS clinician before publication · 6 min read · Published April 2026

Overview

The FMA-UE is the most-used upper-limb outcome measure in stroke research, but its MCID changes by phase of recovery and severity stratum. Reporting "the MCID is 5 points" is wrong more often than right.

Key Findings

• →["33-item, 66-point ordinal scale assessing UE motor impairment in stroke; gold-standard impairment-level UE outcome", "Excellent reliability (ICC at least 0.95) and validity; minimal floor effect, mild ceiling effect in patients with subtle residual deficits", "MCID varies by recovery phase and severity: ~5 points (chronic mild-moderate, Page 2012); ~9-10 points (subacute, Arya 2011); ~13 points (acute moderate-severe, Huynh 2023)", "MDC approximately 5.2 points in chronic stroke — changes below this cannot be distinguished from measurement error", "Correlates strongly with ARAT, WMFT, MAL, and Stroke Impact Scale Hand domain"]

The Study

The Fugl-Meyer Assessment Upper Extremity (FMA-UE) is a 33-item, 66-point impairment-level measure of motor recovery after stroke, scored on a 0-2 ordinal scale per item (0 = cannot perform, 1 = partially, 2 = fully). It assesses voluntary movement against the synergy patterns Brunnstrom described: flexor synergy emergence, extensor synergy, movements combining synergies, and movements out of synergy. It is the gold-standard impairment-level UE measure in stroke RCTs and is widely used as a primary outcome.

The psychometrics are excellent. Inter-rater reliability ICC at least 0.95. Test-retest ICC at least 0.97. Internal consistency Cronbach's alpha at least 0.95. Concurrent validity is strong against the Action Research Arm Test, Wolf Motor Function Test, and Motor Activity Log. The measure has minimal floor effect even in severe impairment but does have ceiling effects in mild impairment — a patient with subtle residual deficits can score 60+ on the FMA-UE while still having functional difficulty.

The MCID, however, is not a single number. The published MCID values differ by population and method:

- Page et al. (2012): MCID 4.25-7.25 points in chronic stroke with mild-moderate impairment, anchor-based using global rating of change. Often cited as approximately 5 points.

- Arya et al. (2011): MCID approximately 9-10 points in subacute stroke (6-24 weeks post), anchor-based.

- Hiraoka et al. (2019): MCID 6.6 points in convalescent (subacute) stroke, moderate-severe impairment.

- Huynh et al. (2023): MCID 13 points in moderate-to-severe acute stroke (1-6 weeks), anchor-based with ROC analysis.

The pattern is consistent: the MCID is larger when impairment is more severe and recovery potential is higher (acute, severe), and smaller when recovery is slower and ceiling effects dominate (chronic, mild).

The Minimal Detectable Change (MDC) — the smallest change that exceeds measurement error — is approximately 5.2 points (See & Hung 2013) for the FMA-UE in chronic stroke. A change smaller than MDC cannot be confidently distinguished from measurement noise.

The practical implication: when interpreting an FMA-UE change score, you need to know which phase of recovery the patient is in and which MCID was derived in that population. Reporting "the patient improved 6 points, exceeding the MCID" is meaningful in chronic mild-moderate impairment but not in moderate-severe acute stroke, where 6 points may not exceed measurement noise.

Clinical Implications

The FMA-UE remains the most defensible single UE outcome measure for stroke. Its weakness is interpretive: clinicians and researchers routinely cite a single MCID without specifying the population it was derived in. Anchoring the chosen MCID to the patient's recovery phase and impairment severity is the standard of care.

Clinic Action Plan

• →Use FMA-UE at admission, mid-treatment, and discharge for any patient with UE motor impairment. Score it consistently — same examiner, same setup, same instructions — to minimize measurement error. When interpreting change: identify the patient's phase (acute under 6 weeks; subacute 6 weeks to 6 months; chronic over 6 months) and severity (FMA-UE score: 0-22 severe, 23-43 moderate, 44-66 mild). Use the MCID derived in the matching population. Document the source of the MCID you used. A change of 5+ points in a chronic mild-moderate patient is a defensible improvement. A change less than 5 points in any population is below MDC and should not be interpreted as real change. Pair with an activity-level measure (ARAT or WMFT) and a self-report measure (MAL or Stroke Impact Scale Hand) — impairment-level changes do not always translate to activity-level changes, and capturing all three levels (impairment, activity, participation) tells the full story.

Sources

[{"citation":"Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S. The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance. Scand J Rehabil Med. 1975;7(1):13-31.","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/1135616/"},{"citation":"Page SJ, Fulk GD, Boyne P. Clinically important differences for the upper-extremity Fugl-Meyer Scale in people with minimal to moderate impairment due to chronic stroke. Phys Ther. 2012;92(6):791-798.","doi":"10.2522/ptj.20110009","url":"https://pubmed.ncbi.nlm.nih.gov/22282773/"},{"citation":"Huynh BP, DiCarlo JA, Vora I, et al. Sensitivity to Change and Responsiveness of the Upper Extremity Fugl-Meyer Assessment in Individuals With Moderate to Severe Acute Stroke. Neurorehabil Neural Repair. 2023;37(8):545-554.","doi":"10.1177/15459683231186985","url":"https://pubmed.ncbi.nlm.nih.gov/37431873/"}]

FAQ

[{"question":"Should I use the full 33-item FMA-UE or a short form?","answer":"The full version is the standard in research and remains the most defensible. Short-form versions (e.g., the 12-item Hsieh) trade some psychometric strength for time savings; they're acceptable in busy clinics but not ideal for outcome research."},{"question":"What's the difference between FMA-UE and FMA-Sensory or FMA-Coordination?","answer":"The full Fugl-Meyer Assessment includes motor (UE 66 pts, LE 34 pts), balance, sensation, range of motion, and pain subscales. FMA-UE specifically refers to the upper extremity motor subscale."},{"question":"Does FMA-UE predict community-level function?","answer":"Indirectly. It correlates with ARAT and WMFT but does not measure ADL or community participation. For community-level outcomes pair with Stroke Impact Scale, MAL, or Reintegration to Normal Living Index."},{"question":"How long does it take to administer?","answer":"Typically 25-35 minutes with an experienced examiner. Trained examiners following the published instructions are essential — interrater reliability falls when scoring conventions are not strictly followed."}]

Every Monday

This is what every Monday brief looks like.

One paper. Plain language. A Clinic Action Plan you can use the same day. Free forever. No credit card.

Already subscribed? Sign up for an account to read the full archive →